Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age.

J Clin Immunol · 2015 · PMC4572047 · PMID 26336818

Europe PMC DOI

hedged sentence

0.3600

closest p · 7.2× alpha

0.3600

boldest claim

The sentences

did not reach statistical significancep = 0.36not close (p > 0.1)

Among 74 patients for whom length parameters were available, there was an overall increase in length percentile of 2 % (SD = 18), but this did not reach statistical significance ( p = 0.36) (Fig. 3 A-D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.